Lanerkitug

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A human immunoglobulin G1 (IgG1) afucosylated monoclonal antibody against C-C-chemokine receptor 8 (CCR8), with potential immunomodulating and antineoplastic activities. Upon administration, lanerkitug targets, binds to and blocks the activity of CCR8 on CCR8-positive tumor-infiltrating regulatory T-cells (Tregs) in the tumor microenvironment (TME) and prevents chemokine ligand 1 (CCL1)-CCR8-mediated signaling. Lanerkitug eliminates CCR8-positive Tregs via the induction of Fc-mediated antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody dependent cellular phagocytosis (ADCP), thereby depleting CCR8-positive Tregs. This may reactivate antitumor immune responses. CCR8 is specifically expressed on activated tumor-infiltrating Tregs in multiple types of cancer and plays a key role in immunosuppression. High expression is correlated with poor prognosis.

**Synonyms:** - Anti-CCR8 Monoclonal Antibody BAY3375968 - BAY 3375968 - BAY-3375968 - BAY3375968 - LANERKITUG